Pharming Group Q4 Revenue Rises 15% to $106.5M

Q4 Performance Highlights

Pharming Group NV announced fourth-quarter revenue of $106.5 million, a 15% increase year-over-year. For the full year, revenue reached $376 million, representing 26% growth compared to the prior year. The company posted a fourth-quarter operating profit of $6.2 million.

Key Growth Drivers

The revenue increase was propelled by strong product performance. Sales for Ruconest grew 9% year-over-year to $87 million. Joenja sales demonstrated significant momentum, surging 52% year-over-year to $20 million in the quarter. The company also reported continued growth in the number of patients receiving paid therapy.

Company Outlook and Projections

Pharming reaffirmed its guidance for the upcoming fiscal year, projecting total revenues between $405 million and $425 million. This forecast implies an 8% to 13% year-over-year growth, driven by expected continued expansion in US and international markets for its key drugs.

Summary

Pharming Group's strong quarterly results, led by accelerating Joenja sales, underscore a solid growth trajectory. The company's positive revenue forecast for the next fiscal year signals confidence, despite planned increases in operating expenses to support crucial research and development.

FAQ

Q: What was Pharming Group's total revenue in the fourth quarter?
A: Pharming Group reported fourth-quarter revenue of $106.5 million, a 15% increase compared to the same period last year.

Q: What is Pharming Group's revenue forecast for the next fiscal year?
A: The company expects total revenues to be between $405 million and $425 million.

Source: Investing.com